![Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets ( Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study | springermedizin.de Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets ( Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study | springermedizin.de](https://media.springernature.com/lw400/springer-static/cover/journal/10549/145/2.jpg?as=jpg)
Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets ( Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study | springermedizin.de
Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets ( Gynoflor[R]) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study - Document - Gale OneFile:
![Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets ( Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study | Breast Cancer Research and Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets ( Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study | Breast Cancer Research and](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-014-2930-x/MediaObjects/10549_2014_2930_Fig5_HTML.gif)